{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"30","value":"16"}]}],"title":"Grade II-IV GvHD (MRD n=38)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"39","value":"26"}]}],"title":"Grade II-IV GvHD (MUD n=53)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24","upperLimit":"65","value":"46"}]}],"title":"Grade II-IV GvHD (HAPLO n=33)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"12","value":"3"}]}],"title":"Grade III-IV GvHD (MRD n=38)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"25","value":"13"}]}],"title":"Grade III-IV GvHD (MUD=53)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"47","value":"27"}]}],"title":"Grade III-IV GvHD (HAPLO n=33)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"description":"Estimate toxicity including graft-versus-host disease (GVHD) in participants treated with an alemtuzumab T cell depleted, reduced intensity preparative regimen followed by allogeneic hematopoietic transplantation. Bone marrow aspiration and/or biopsy were performed 3-5 weeks after transplant to assess donor-cell engraftment. Acute or chronic GVHD was diagnosed and graded according to standard criteria. Toxicity was formally graded using the National Cancer Institute Common Toxicity Criteria version 3.0.","dispersionType":"95% Confidence Interval","groups":[{"description":"Non-myeloablative Stem Cell Transplant (SCT): Donor will receive Granulocyte colony-stimulating factor (G-CSF) 8 mcg/kg/d subcutaneously twice daily for 4 days, until pheresis is completed or until white blood cells \\> 100,000. Recipients will be premedicated with Benadryl 50 mg intravenously (IV) or orally (PO), and acetaminophen 650 mg PO (or hydrocortisone 50-100 mg IV on first day). The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. The prep regimen for myeloid disease will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours.The Peripheral Blood Stem Cells (PBSCs) will be infused over 2-4 days. Participant evaluations will occur 2 times per week by physical exam for toxicity through day 45.","id":"OG000","title":"Cohort A & B - Lymphoid & Myeloid Disease"}],"paramType":"NUMBER","populationDescription":"All participants who received transplant. Cohort A (n=62) had acute or chronic leukemia (ALL or CLL), lymphoma, or myeloma. Cohort B (n=62) had acute or chronic myeloid leukemia (AML or CML), myelodysplastic disorder or myeloproliferative disorder. Analysis by occurrence of Graft versus Host Disease (GvHD) and Graft Failure and donor type.","reportingStatus":"POSTED","timeFrame":"180 days","title":"Graft Versus Host Disease","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}